Iceland Seafood International hf: Q1 2023 results and investors meeting
Iceland Seafood will publish its Interim Financial Statement for Q1 2023 after closing of markets on May 17th 2023. The same day at 4.15pm, the company will host a meeting for investors and market participants, where management will present and discuss the results. The meeting will be held at the company‘s premises at Köllunarklettsvegur 2, 104 Reykjavík. The meeting will also be webcasted live in Icelandic, participants to the online meeting can send questions in writing prior and during the meeting to the email investors@icelandseafood.com. See link to the webcast below.
https://vimeo.com/event/3401613/embed/675ea70904
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Scatec closes transaction to divest Upington solar plants in South Africa1.6.2023 08:30:00 CEST | Press release
Oslo/Cape Town 1 June 2023: Scatec ASA, a renewable energy frontrunner in emerging markets, today closed the previously announced transaction to divest the Upington solar plants in South Africa. The gross consideration for divestment of Scatec’s 42% equity-share in the 258-megawatt (MW) plants is ZAR 973 million (NOK 546 million). As previously communicated the proceeds will be recycled into new investments within renewable energy. “We are very pleased to secure a value accretive transaction, in line with our strategy to optimise our portfolio and recycle capital. South Africa remains a focus market for us, and we will continue to build scale through new investments in the country. I would like to thank all parties involved in the transaction,” says Scatec CEO Terje Pilskog The net accounting gain is estimated to be NOK 791 million on a consolidated basis and NOK 348 million on a proportionate basis. The difference is primarily explained by the D&C margin related to the projects which
The board and management of Terranet subscribe in the ongoing rights issue1.6.2023 08:30:00 CEST | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Members of Terranet AB's board and management intend to subscribe in the ongoing rights issue. Göran Janson intends to subscribe for all his held rights, whilst Torgny Hellström and Magnus Andersson will subscribe with rights transferred to them by Anders Blom. Further, Anders will subscribe privately for his remaining rights, in addition to the subscription commitment of SEK 13.0 million that Anders has made through Maida Vale Capital AB. Terranet has received commitments from the following persons who intend to subscribe in the Company's ongoing rights issue, privately or thro
Medlemmar i styrelse och ledning för Terranet avser att teckna i den pågående företrädesemissionen1.6.2023 08:30:00 CEST | Pressemelding
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, NYA ZEELAND, HONGKONG, JAPAN, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER NÅGON ANNAN JURISDIKTION DÄR DISTRIBUTION AV DETTA PRESSMEDDELANDE INTE SKULLE VARA FÖRENLIG MED TILLÄMPLIGA FÖRESKRIFTER. VÄNLIGEN SE VIKTIG INFORMATION I SLUTET AV PRESSMEDDELANDET. Medlemmar av TerranetABsstyrelse och ledningavser att teckna i den pågående företrädesemissionen. Göran Janson avser nyttja samtliga av sina uniträtter, medan Torgny Hellström och Magnus Andersson kommer att teckna med uniträtter som överlåtits vederlagsfritt från Anders Blom i syfte att säkerställa tilldelning. Anders kommer vidare att använda samtliga av sina återstående uniträtter för att teckna privat, utöver den teckningsförbindelse om 13,0 MSEK som Anders ingått genom Maida Vale Capital AB. Terranet har mottagit teckningsåtaganden från följande personer som avser teckna i Bolagets pågående företrädesemission, privat e
Wolters Kluwer appoints Bas Kniphorst as Executive Vice President and Managing Director, Tax & Accounting Europe1.6.2023 08:30:00 CEST | Press release
Wolters Kluwer appoints Bas Kniphorst as Executive Vice President and Managing Director, Tax & Accounting Europe Alphen aan den Rijn –June 1, 2023 -Wolters Kluwer Tax & Accounting (TAA), a leading global provider of software, integrated workflow solutions, and information for tax, accounting, audit, and compliance professionals, today announced the appointment of Bas Kniphorst as Executive Vice President and Managing Director for TAA Europe, effective June 1. Kniphorst was previously Vice President and Managing Director of Wolters Kluwer Legal & Regulatory (LR), Benelux. Jason Marx, CEO of Wolters Kluwer TAA, commented: “Bas has a deep understanding of the tax and accounting market with a long track record of driving customer-driven innovation, transformation, and growth. He also has invaluable knowledge of our products, and customer requirements. I’m excited to work with him as we drive further innovation and growth for the division across Europe.” Kniphorst joined Wolters Kluwer in 2
Philogen Announces Clinical Trial Collaboration with MSD1.6.2023 08:30:00 CEST | Press release
The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy™ in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in stage III and IV unresectable melanoma patients who previously failed treatment with checkpoint inhibitors Siena, Italy, June 1st, 2023 - Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative medicines based on tumor-targeting antibodies and small molecule ligands, announces that it has entered into a Clinical Trial Collaboration and Supply Agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA). Under the terms of the supply agreement, MSD provides their anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), to be evaluated in combination with Philogen's immunocytokines L19IL2, L19TNF, and Nidlegy™ in a randomized Phase II clinical trial. The study provides an opportunity to explore the combination of immunocytokines and PD-1 blockade in stage III and IV unresectable me